Synthaverse S.A. (WAR:SVE) — Market Cap & Net Worth
Market Cap & Net Worth: Synthaverse S.A. (SVE)
Synthaverse S.A. (WAR:SVE) has a market capitalization of $60.37 Million (zł219.36 Million) as of September 17, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #21272 globally and #186 in its home market, demonstrating a -4.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Synthaverse S.A.'s stock price zł2.90 by its total outstanding shares 75770575 (75.77 Million). Also see how large is Synthaverse S.A.'s balance sheet for a full breakdown of the balance sheet.
Synthaverse S.A. Market Cap History: 2015 to 2026
Synthaverse S.A.'s market capitalization history from 2015 to 2026. Data shows change from $43.58 Million to $60.37 Million (-0.02% CAGR). Also see Synthaverse S.A. (SVE) cash conversion ratio for how efficiently the company converts equity into cash flow.
Synthaverse S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Synthaverse S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Synthaverse S.A. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.31x
Synthaverse S.A.'s market cap is 1.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.48x
Synthaverse S.A.'s market cap is 12.48 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $43.58 Million | $42.59 Million | -$37.24 Million | 1.02x | N/A |
| 2016 | $23.77 Million | $36.34 Million | -$23.48 Million | 0.65x | N/A |
| 2017 | $30.45 Million | $31.40 Million | $588.00K | 0.97x | 51.78x |
| 2018 | $21.90 Million | $32.29 Million | -$32.41 Million | 0.68x | N/A |
| 2019 | $21.90 Million | $39.11 Million | $2.48 Million | 0.56x | 8.82x |
| 2020 | $186.84 Million | $40.16 Million | $4.44 Million | 4.65x | 42.09x |
| 2021 | $92.59 Million | $41.15 Million | $4.25 Million | 2.25x | 21.79x |
| 2022 | $124.91 Million | $50.38 Million | $6.08 Million | 2.48x | 20.54x |
| 2023 | $89.04 Million | $58.61 Million | $4.76 Million | 1.52x | 18.71x |
| 2024 | $94.26 Million | $71.76 Million | $7.55 Million | 1.31x | 12.48x |
Competitor Companies of SVE by Market Capitalization
Companies near Synthaverse S.A. in the global market cap rankings as of September 17, 2026. Review SVE goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Synthaverse S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Synthaverse S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Synthaverse S.A.'s market cap moved from $43.58 Million to $ 60.37 Million, with a yearly change of -0.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł60.37 Million | -20.68% |
| 2025 | zł76.11 Million | -19.25% |
| 2024 | zł94.26 Million | +5.85% |
| 2023 | zł89.04 Million | -28.71% |
| 2022 | zł124.91 Million | +34.91% |
| 2021 | zł92.59 Million | -50.45% |
| 2020 | zł186.84 Million | +753.33% |
| 2019 | zł21.90 Million | 0.00% |
| 2018 | zł21.90 Million | -28.08% |
| 2017 | zł30.45 Million | +28.07% |
| 2016 | zł23.77 Million | -45.45% |
| 2015 | zł43.58 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Synthaverse S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.37 Million USD |
| MoneyControl | $60.37 Million USD |
| MarketWatch | $60.37 Million USD |
| marketcap.company | $60.37 Million USD |
| Reuters | $60.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Synthaverse S.A.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more